Progyny (PGNY) has entered into a revolving credit facility which makes available to the Company up to $200M in aggregate revolving credit commitments, which the Company can utilize for revolving credit borrowings, subject to customary borrowing conditions, until maturity on July 1, 2030. The facility is expected to enhance the Company’s operational and financial flexibility beyond its current ability to generate significant cash flow. The revolver is undrawn, and the Company has no planned use for the facility at this time. The Company’s capital priorities, which include the evaluation of stock repurchases, the expansion of its product portfolio, investments in new distribution channels, and select acquisitions, remain unchanged.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY:
- Hinge Health, Progyny partnership ‘mutually beneficial,’ says Morgan Stanley
- Progyny adds pelvic floor therapy to its offerings
- Progyny joins Amazon’s Health Benefits Connector program
- Progyny adds Elizabeth Bierbower to board of directors
- Progyny Stockholders Meeting Highlights Governance Decisions